Scotland, Wales & NI: How NHS Peptide Access Differs from England

The United Kingdom has a devolved health system: whilst the broad principles of NHS care are shared, health policy, commissioning, and drug approval decisions are made separately in England (NHS England), Scotland (NHS Scotland), Wales (NHS Wales / Gwasanaeth Iechyd Gwladol Cymru), and Northern Ireland (Health and Social Care Northern Ireland, HSCNI).

This devolution means that: - The regulatory approval process (MHRA) is UK-wide — all four nations use the same licensed medicines - But the funding and prescribing recommendations are made by different bodies: NICE (England and Wales technically, but Wales has its own assessment), SMC (Scotland), and AWMSG (Wales) and the Medicines Management Programme (Northern Ireland) - Free prescriptions apply differently — a policy difference with direct financial implications for patients

The four bodies that determine NHS prescribing access: - NICE (National Institute for Health and Care Excellence): Technology Appraisals cover England; Wales uses NICE guidance as a starting point but AWMSG can issue independent guidance - SMC (Scottish Medicines Consortium): Scotland's body for appraising new medicines for NHS Scotland use; operates independently of NICE - AWMSG (All Wales Medicines Strategy Group): Wales-specific body for medicines not covered by NICE, or where Wales chooses to conduct its own assessment - MMG/HSC (Medicines Management Programme / Health and Social Care): Northern Ireland's system, which largely but not always follows NICE guidance with occasional independent assessment

A drug approved by NICE for England does not automatically become available on NHS Scotland or Wales — it must also be reviewed and accepted by the relevant national body.

One of the most practically significant differences for patients across the four nations is NHS prescription charging — and the divergence is stark.

Scotland: All NHS prescriptions in Scotland are free of charge regardless of the medication, patient age, or condition. This has been the case since 2011. For patients requiring expensive GLP-1 medications such as Ozempic, Wegovy or Mounjaro on NHS prescription, this is a substantial financial benefit.

Wales: All NHS prescriptions in Wales are also free of charge, following the abolition of prescription charges in 2007. Welsh patients accessing GLP-1 medications through NHS Wales specialist services pay nothing for the prescription itself.

England: NHS prescriptions in England carry a standard charge of £9.90 per item (2026 rate). Some patients are exempt (those with specified chronic conditions, over 60s, under 16s, those on qualifying benefits). For high-cost specialist medications like Wegovy, the dispensing is typically managed through specialist pharmacy arrangements — patients in specialist weight management services may receive their medication directly without the standard prescription charge applying in the same way, depending on local arrangements.

Northern Ireland: Northern Ireland abolished prescription charges in 2010. Like Scotland and Wales, NHS prescriptions are free for all patients at the point of dispensing.

Practical implication: For a Scottish or Welsh patient who gains access to NHS Wegovy or Mounjaro through their specialist weight management service, the medication costs them nothing beyond their taxes. For an English patient on the equivalent pathway, there may be prescription charges depending on their exemption status and how the medication is supplied.

The existence of three separate medicines appraisal bodies means that identical medications can become available at different times in different parts of the UK, even after MHRA licensing.

NICE (England — and as a default for Wales): - NICE Technology Appraisal TA875 (October 2023): Approved Wegovy (semaglutide 2.4 mg) for NHS use in England for chronic weight management within Tier 3 specialist services - NICE TA1026 (March 2025): Approved Mounjaro (tirzepatide) for NHS weight management in England

SMC (Scotland): - The SMC accepted semaglutide 2.4 mg (Wegovy) for restricted use in NHS Scotland for weight management in adults with obesity and at least one comorbidity — broadly equivalent criteria to NICE, but under a separate SMC submission timeline - Tirzepatide (Mounjaro) for weight management was accepted by the SMC in a separate process; access in Scotland is through specialist weight management services as in England - Importantly, SMC approvals do not automatically follow NICE approvals — there have been cases where NHS England patients have had access to a drug for 12–24 months before Scottish approval

AWMSG (Wales): - Wales often implements NICE Technology Appraisals directly — NICE guidance is expected to be adopted by NHS Wales within a specified timeframe - However, AWMSG can also conduct independent assessments; for GLP-1 medications, Welsh health boards have generally followed the NICE pathway

Northern Ireland: - HSCNI largely follows NICE guidance but has the authority to make independent commissioning decisions - The NI Medicines Management Programme issues guidance to GPs and secondary care in Northern Ireland; for complex specialist medicines like GLP-1 weight management drugs, access is through equivalent specialist services

Beyond drug approval status, the practical availability of NHS GLP-1 treatment depends on specialist service capacity — and this varies not just between nations but within each nation.

Scotland: NHS Scotland has invested in specialist weight management services, but capacity remains limited particularly in remote and rural areas (which constitute a substantial proportion of Scottish geography). NHS Highland and other rural health boards have significantly different access timescales compared to NHS Greater Glasgow and Clyde or NHS Lothian. Telehealth-enabled specialist services have partially addressed this gap.

In Scotland's largest boards, waiting times for Tier 3 equivalent services (known as Level 3 weight management services in Scottish terminology) were reported at 12–18 months as of 2025, comparable to many English ICBs.

Wales: NHS Wales has developed weight management pathways through its health board structure. Betsi Cadwaladr (North Wales) and Aneurin Bevan (South East Wales) health boards have different service configurations and waiting times. A Welsh government commitment to expand weight management capacity was announced in 2024, but service development is ongoing.

Northern Ireland: HSCNI weight management services have historically been concentrated in Belfast Trust and South Eastern Trust areas, with longer wait times for patients in more rural parts of Northern Ireland (Derry, Fermanagh, Tyrone). Cross-border considerations are relevant for patients in border counties who may have geographic access to Republic of Ireland healthcare options, though NHS cross-border funding is complex.

Key message: Waiting times and service availability vary considerably within each nation, not just between them. Contact your GP to understand the specific situation in your health board or integrated care board area.

A question that arises for some patients is whether they can access NHS treatment in another UK nation — for example, if a Scottish patient wanted to access a treatment available in England before it was approved by the SMC.

The general principle: NHS treatment is ordinarily provided in the country of residence. A Scottish patient registered with an NHS Scotland GP is funded through NHS Scotland; they would not routinely receive NHS England treatment funded by NHS Scotland for a condition that can be managed within Scotland.

Cross-border treatment in practice: - Planned cross-border referrals can occur for genuinely specialist services not available in a patient's home nation — funded through agreed inter-country arrangements - For weight management and GLP-1 medications, there is no established cross-border pathway between the four nations; patients in Scotland, Wales or Northern Ireland cannot simply register with an English GP to access NICE-approved treatments ahead of their national approval

Practical alternatives: - Private healthcare: Available equally across all four nations; removes the national approval issue entirely — a Scottish or Welsh patient can access private Wegovy or Mounjaro through exactly the same private prescribing pathways as an English patient - Clinical trial participation: Some trials recruiting in England may accept Scottish or Welsh participants; check clinicaltrials.gov for trials relevant to your condition

Devolution and patient equity: The system creates genuine health inequality — a patient in Scotland or Wales with severe obesity may wait longer or have different access criteria compared to an English patient for the same medication. This is an acknowledged tension within the devolved NHS structure, and advocacy organisations including Obesity UK have called for greater parity.

Based on the above, here is a practical summary for patients in each devolved nation seeking GLP-1 weight management treatment.

Scotland: 1. Speak to your GP — they can refer to specialist Level 3 weight management services available in your health board 2. Confirm whether Wegovy or Mounjaro are listed on your health board's formulary following SMC acceptance 3. Free prescriptions apply — if you gain NHS access, you will not pay for the medication 4. For faster access, private UK telehealth platforms (CQC-registered, serving Scotland) offer equivalent care to private weight loss clinics in England 5. Contact Obesity UK Scotland or Counterweight for additional support navigating the pathway

Wales: 1. GP referral to specialist weight management services through your local health board 2. NHS Wales implements NICE guidance — Wegovy and Mounjaro should be available through specialist services following NICE approval 3. Free prescriptions apply 4. Public Health Wales and local health boards publish weight management service information 5. Welsh language services are available in some areas; your health board website can confirm availability

Northern Ireland: 1. GP referral to HSC specialist weight management services 2. NICE guidance is generally followed; confirm current formulary status with your GP or the Medicines Management Programme 3. Free prescriptions apply in Northern Ireland 4. Southern Health and Social Care Trust and other trusts have patient-facing information on weight management referrals 5. Private weight loss clinics in Northern Ireland (particularly Belfast) offer private GLP-1 prescribing as in England

Across all nations: - Inform your GP explicitly that you are interested in GLP-1 weight management medication and ask about the pathway in your area - Maintaining a documented record of previous weight management attempts strengthens your referral case - Private options exist equally across all UK nations and are not subject to national drug approval differences

*This article is for general educational purposes. NHS policies, formulary decisions, and service configurations change frequently. Always verify current information directly with your GP or the relevant health board or trust.*